Novartis forms alliance with Bristol-Myers

Novartis signs deal with US group Keystone

Swiss healthcare group, Novartis, has formed an alliance with the United States firm, Bristol-Myers Squibb, to develop and promote Novartis's new irritable bowel syndrome (IBS) treatment, Zelmac.

This content was published on October 18, 2000 - 10:06

The drug, which Novartis intends to launch in the US in the first half of next year, pending approval by the US regulatory authorities, is the main focus of the company's promotion drive in 2001.

The US market is considered to be a key target for the new treatment.

The alliance, which excludes Japan, will promote Zelmac to doctors and strengthen Novartis' efforts to educate consumers about IBS.

Novartis said the ailment affects millions of people but its symptoms are often not clearly defined or understood.

The two firms will also collaborate in the development of two Bristol-Myers immune modulating compounds.

swissinfo with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know:

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Change your password

Do you really want to delete your profile?